Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
West Palm Beach, FL
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Columbus, GA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Columbus, GA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Macon, GA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Macon, GA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Savannah, GA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
South Bend, IN
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
South Bend, IN
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Overland Park, KA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
New Orleans, LA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Grand Blanc, MI
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Butte, MT
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Butte, MT
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Omaha, NE
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Brooklyn, NY
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Carlisle, OH
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Carlisle, OH
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Tulsa, OK
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Corvallis, OR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Corvallis, OR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Gresham, OR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Gresham, OR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Portland, OR
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Hazleton, PA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Hazleton, PA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Dallas, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Duncanville, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Duncanville, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Fort Worth, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Houston, TX
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Layton, UT
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Layton, UT
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Charlottesville, VA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated:  2/25/2016
GSK Investigational Site
mi
from
Seattle, WA
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus
Status: Enrolling
Updated: 2/25/2016
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Weekly LOC-paclitaxel Injection for Melanoma
Phase I Study of Weekly LOC-paclitaxel Injection
Status: Enrolling
Updated:  2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Weekly LOC-paclitaxel Injection for Melanoma
Phase I Study of Weekly LOC-paclitaxel Injection
Status: Enrolling
Updated: 2/25/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated:  2/25/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated: 2/25/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated:  2/25/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status: Enrolling
Updated: 2/25/2016
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Status: Enrolling
Updated:  2/26/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma
Status: Enrolling
Updated: 2/26/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Mobile, AL
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Mobile, AL
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Little Rock, AR
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Duarte, CA
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
La Jolla, CA
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Daytona Beach, FL
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Miami Beach, FL
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Louisville, KY
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
St. Louis, MO
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Omaha, NE
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Omaha, NE
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Morristown, NJ
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
New York, NY
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Winston Salem, NC
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Canton, OH
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Portland, OR
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Greenville, SC
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated:  2/26/2016
Clinical Research Facility
mi
from
Dallas, TX
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma
Status: Enrolling
Updated: 2/26/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials